|
|
|
|
| Though the number of CDMOs with mRNA/RNA capabilities is increasing, many of these are better equipped for large-scale, linear mRNA development. Don't miss Advancing RNA Live on January 21st as our panel shares how mRNA and next-gen RNA modality companies need to be evaluating CDMO platforms. Attendance is free thanks to the support of Cytiva. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|